Sandbox/00008: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 92: Line 92:


❑&nbsp;&nbsp;± Correct [[tachyarrhythmia|<span style="color: #000000;">tachy-</span>]] or [[bradyarrhythmia|<span style="color: #000000;">bradyarrhythmia</span>]]
❑&nbsp;&nbsp;± Correct [[tachyarrhythmia|<span style="color: #000000;">tachy-</span>]] or [[bradyarrhythmia|<span style="color: #000000;">bradyarrhythmia</span>]]


❑&nbsp;&nbsp;± [[mechanical ventilation|<span style="color: #000000;">Ventilatory support</span>]]</div>}}
❑&nbsp;&nbsp;± [[mechanical ventilation|<span style="color: #000000;">Ventilatory support</span>]]</div>}}

Revision as of 01:01, 5 May 2014

Cardiogenic Shock
Resident Survival Guide
Overview
Causes
FIRE
Emergency Revascularization
Complete Diagnostic Approach
Criteria
Hemodynamic Optimization
Do's
Don'ts

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.[1]

Boxes in red signify that an urgent management is needed.

Abbreviations: CBC, complete blood count; CI, cardiac index; CK-MB, creatine kinase MB isoform; CVP, central venous pressure; DC, differential count; ICU, intensive care unit; INR, international normalized ratio; LFT, liver function test; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; PT, prothrombin time; PTT, partial prothrombin time; SaO2, arterial oxygen saturation; SBP, systolic blood pressure; ScvO2, central venous oxygen saturation; SvO2, mixed venous oxygen saturation; SMA-7, sequential multiple analysis-7.

 
 
 
 
 
 
 
Does the patient have cardinal findings that increase the pretest probability of cardiogenic shock?

❑  Evidence of end-organ hypoperfusion

❑  Altered mental status
❑  Cold extremities
❑  Cyanosis
❑  Oliguria (urine output <0.5 mL/kg/h)
❑  Sustained hypotension (≥30 min)
❑  SBP <90 mm Hg or
❑  MAP ↓ >30 mm Hg below baseline
❑  Presence of myocardial dysfunction after exclusion or correction of non-myocardial factors contributing to tissue hypoperfusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
 
 
NO
 
 
 
Cardiogenic shock suspected
(click for details on criteria)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immediate steps
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial workup

❑  Arterial blood gas

❑  CBC/DC/SMA-7/LFT/PT/PTT/INR

❑  Cardiac troponins, CK-MB

❑  BNP, NT-proBNP

❑  Lactate

❑  12-Lead ECG

❑  Chest radiograph

❑  Echocardiography
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maintain adequate blood pressure
(click for details)
 
 
 
 
 
 
 
 
 
 
 

SBP <70 mm Hg:

❑  Norepinephrine IV infusion

❑  Initial dose: 0.5–1.0 μg/min
❑  Maximum dose: 30–40 μg/min
❑  Titrate to SBP >90 mm Hg

SBP 70–100 mm Hg with symptoms:

❑  Dopamine

❑  oooo IV infusion

SBP 70–100 mm Hg without symptoms:

❑  Dobutamine

❑  oooo IV infusion

SBP >100 mm Hg:

❑  Nitroglycerin

❑  oooo IV infusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute coronary syndrome likely?

❑  New ECG changes suggestive of AMI

❑  ± Positive cTnT, cTnI, or CK-MB

❑  ± Symptoms of myocaridal ischemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Optimize hemodynamic status
(click for details)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preload

Goal: PCWP 15–18 mm Hg, CVP 8–12 cm H2O

❑  Fluid challenge protocol ("TROL")

❑  ± Correct pulmonary congestion

❑  ± Furosemide 40 mg slow IV injection
❑  ± Morphine 2–4 mg slow IV injection
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Afterload

Goal: MAP >65 mm Hg, SVR 800–1200 dyn·s·cm−5

❑  If ↑ MAP & ↑ SVR: wean vasopressors ± vasodilators

❑  If ↓ MAP & ↑ SVR: vasopressors + inotropes

❑  If ↓ MAP & ↓ SVR: vasopressors ± vasopressin

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiac index

Goal: CI >2.2 L/min/m2

❑  ± Dobutamine

❑  ± Milrinone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluate perfusion and oxygenation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endpoints:

❑  SaO2 >92%

❑  SvO2 >60%

❑  ScvO2 >70%

❑  Urine output >0.5 mL/kg/h

❑  Lactate <2.2 mM/L

❑  Hematocrit ≥30%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If hypoperfusion persists:
❑  Consider IABP, VAD, or ECMO if indicated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Emergency Revascularization [Return to FIRE]

Criteria [Return to FIRE]

Criteria for Cardiogenic Shock [Return to FIRE]

Criteria for Acute Myocardial Infarction [Return to FIRE]

  • Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and with at least one of the following:[8]
  • Recent episode of typical ischemic discomfort that either is of new onset or is severe or that exhibits an accelerating pattern of previous stable angina (especially if it has occurred at rest or is within 2 weeks of a previously documented MI)
  • Chest pain or severe epigastric pain, nontraumatic in origin, with components typical of myocardial ischemia or MI:
  • Central/substernal compression or crushing chest pain
  • Pressure, tightness, heaviness, cramping, burning, aching sensation
  • Unexplained indigestion, belching, epigastric pain
  • Radiating pain in neck, jaw, shoulders, back, or 1 or both arms


Mainetenance of Blood pressure [Return to FIRE]

content here

Hemodynamic Optimization [Return to FIRE]

Preload

Fluid Challenge Protocol
  • Protocolized fluid administration titrated to hemodynamic and clinical endpoints secures the efficacy of tissue perfusion and oxygenation.[10]
  • Four elements of the fluid challenge protocol: type of fluid (T), rate of fluid administration (R), objective (O), and limits (L).[11]
  • 1. Type of fluid (T)
  • The choice of crystalloid or colloid solution should be made on the basis of the underlying disease, the nature of fluid deficit, the severity of circulatory failure, the serum albumin concentration, and the risk of bleeding.[12]
  • There were no significant differences in mortality between saline and albumin infusion for critically ill patients.[13]
  • Blood transfusion may be considered in the presence of profound anemia or massive hemorrhage.[10]
  • Hyperchloremic acidosis may be associated with the use of isotonic saline solution.[14]
  • 2. Rate of fluid administration (R)
Baseline PCWP (mm Hg) Baseline CVP (cm H2O) Rate of fluid administration
≥16 ≥14 50 mL over 10 minutes
<16 but ≥12 <14 but ≥8 100 mL over 10 minutes
<12 <8 200 mL over 10 minutes
  • 3. Objective (O)
  • Fluid administration should be titrated to reach predetermined clinical endpoints such as resolution of tachycardia or oliguria, improved skin perfusion or level of consciousness, normalization of lactate concentrations, and restoration of adequate blood pressure or ventricular filling pressure.[12]
  • 4. Limits (L)
  • Fluid administration should be stopped if the safety limits are violated to minimize the risk of developing pulmonary edema.
  • Inotropes, vasodilators, or mechanical circulatory device may be required if signs of hypoperfusion persist despite optimal fluid loading.
  • Hemodynamic safety limits based on PCWP (the 7–3 rule) or CVP (the 5–2 rule):[10]
↑ PCWP (mm Hg) ↑ CVP (cm H2O) Action
≥7 ≥5 Stop fluid administration
<7 but >3 <5 but >2 Wait and recheck pressure after 10 minutes
≤3 ≤2 Continue fluid administration
Pulmonary Congestion
  • Findings suggestive of cardiogenic pulmonary edema:[15]
  • History and clinical manifestations
  • Cough
  • Dyspnea
  • Expectoration of frothy sputum
  • Orthopnea
  • Paroxysmal nocturnal dyspnea
  • Signs and symptoms of heart failure
  • Signs and symptoms of hypoxemia
  • Signs and symptoms of myocardial ischemia
  • Signs and symptoms of valvular dysfunction
  • Tachypnea
  • Physical examination
  • Cool extremities
  • Heart murmurs
  • Hepatomegaly
  • Inspiratory crackles or rhonchi
  • Jugular venous distention
  • S3 gallop
  • Peripheral edema
  • Laboratory and hemodynamic findings
  • BNP > 500 pg/mL
  • PCWP >18 mm Hg
  • Radiologic findings
  • Central infiltrates with peripheral sparing
  • Cephalization of pulmonary vessels
  • Enlarged cardiac silhouette
  • Enlargement of peribronchovascular spaces
  • Increased opacity of acinar areas that coalesce into frank consolidations
  • Kerley B lines
  • Peribronchial cuffing
  • Pleural effusions
  • Vascular pedicle width >70 mm
PCWP (mm Hg) Phase of Pulmonary Congestion Findings on Chest Radiograph
18–20 Onset of pulmonary congestion Redistribution of pulmonary flow to the upper lobes ("cephalization") and Kerley lines
20–25 Moderate congestion Diminished clarity of the borders of medium-sized pulmonary vessels ("perihilar haze")
25–30 Severe congestion Radiolucent grapelike clusters surrounded by radiodense fluid ("periacinar rosette")
>30 Onset of pulmonary edema Coalescence of periacinar rosettes resulting in "Bat's wing" opacities
  • Dosage and Administration
  • For acute pulmonary edema, the initial dose is 40 mg injected slowly intravenously (over 1 to 2 minutes).
  • If a satisfactory response does not occur within 1 hour, the dose may be increased to 80 mg injected slowly intravenously (over 1 to 2 minutes).
  • Contraindications
  • Dosage and Administration
  • Morphine may be used adjunctively in the treatment of acute pulmonary edema at a dose of 2–4 mg (slow IV injection over 1–5 minutes) every 5–30 minutes as needed.
  • Contraindications



Afterload

content here

Cardiac Index


Do's

Don'ts

References

  1. Robin, E.; Costecalde, M.; Lebuffe, G.; Vallet, B. (2006). "Clinical relevance of data from the pulmonary artery catheter". Crit Care. 10 Suppl 3: S3. doi:10.1186/cc4830. PMID 17164015.
  2. 2.0 2.1 Califf, RM.; Bengtson, JR. (1994). "Cardiogenic shock". N Engl J Med. 330 (24): 1724–30. doi:10.1056/NEJM199406163302406. PMID 8190135. Unknown parameter |month= ignored (help)
  3. Hollenberg, SM.; Kavinsky, CJ.; Parrillo, JE. (1999). "Cardiogenic shock". Ann Intern Med. 131 (1): 47–59. PMID 10391815. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 Goldberg, RJ.; Gore, JM.; Alpert, JS.; Osganian, V.; de Groot, J.; Bade, J.; Chen, Z.; Frid, D.; Dalen, JE. (1991). "Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988". N Engl J Med. 325 (16): 1117–22. doi:10.1056/NEJM199110173251601. PMID 1891019. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 5.2 Forrester, JS.; Diamond, G.; Chatterjee, K.; Swan, HJ. (1976). "Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts)". N Engl J Med. 295 (24): 1356–62. doi:10.1056/NEJM197612092952406. PMID 790191. Unknown parameter |month= ignored (help)
  6. 6.0 6.1 Forrester, JS.; Diamond, G.; Chatterjee, K.; Swan, HJ. (1976). "Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts)". N Engl J Med. 295 (25): 1404–13. doi:10.1056/NEJM197612162952505. PMID 790194. Unknown parameter |month= ignored (help)
  7. 7.0 7.1 Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter |month= ignored (help)
  8. Thygesen, K.; Alpert, JS.; Jaffe, AS.; Simoons, ML.; Chaitman, BR.; White, HD.; Thygesen, K.; Alpert, JS.; White, HD. (2012). "Third universal definition of myocardial infarction". J Am Coll Cardiol. 60 (16): 1581–98. doi:10.1016/j.jacc.2012.08.001. PMID 22958960. Unknown parameter |month= ignored (help)
  9. Crexells, C.; Chatterjee, K.; Forrester, JS.; Dikshit, K.; Swan, HJ. (1973). "Optimal level of filling pressure in the left side of the heart in acute myocardial infarction". N Engl J Med. 289 (24): 1263–6. doi:10.1056/NEJM197312132892401. PMID 4749545. Unknown parameter |month= ignored (help)
  10. 10.0 10.1 10.2 10.3 Weil, MH.; Henning, RJ. "New concepts in the diagnosis and fluid treatment of circulatory shock. Thirteenth annual Becton, Dickinson and Company Oscar Schwidetsky Memorial Lecture". Anesth Analg. 58 (2): 124–32. PMID 571235.
  11. Vincent, JL. (2011). "Let's give some fluid and see what happens versus the mini-fluid challenge". Anesthesiology. 115 (3): 455–6. doi:10.1097/ALN.0b013e318229a521. PMID 21792055. Unknown parameter |month= ignored (help)
  12. 12.0 12.1 Vincent, JL.; Weil, MH. (2006). "Fluid challenge revisited". Crit Care Med. 34 (5): 1333–7. doi:10.1097/01.CCM.0000214677.76535.A5. PMID 16557164. Unknown parameter |month= ignored (help)
  13. Finfer, S.; Bellomo, R.; Boyce, N.; French, J.; Myburgh, J.; Norton, R. (2004). "A comparison of albumin and saline for fluid resuscitation in the intensive care unit". N Engl J Med. 350 (22): 2247–56. doi:10.1056/NEJMoa040232. PMID 15163774. Unknown parameter |month= ignored (help)
  14. Scheingraber, S.; Rehm, M.; Sehmisch, C.; Finsterer, U. (1999). "Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynecologic surgery". Anesthesiology. 90 (5): 1265–70. PMID 10319771. Unknown parameter |month= ignored (help)
  15. Ware, LB.; Matthay, MA. (2005). "Clinical practice. Acute pulmonary edema". N Engl J Med. 353 (26): 2788–96. doi:10.1056/NEJMcp052699. PMID 16382065. Unknown parameter |month= ignored (help)
  16. 16.0 16.1 Handbook of Emergency Cardiovascular Care for Healthcare Providers. ISBN 1616690003.
  17. "FUROSEMIDE INJECTION [AMERICAN REGENT, INC.]".
  18. "MORPHINE SULFATE INJECTION, SOLUTION, CONCENTRATE".
  19. O'Connor, RE.; Brady, W.; Brooks, SC.; Diercks, D.; Egan, J.; Ghaemmaghami, C.; Menon, V.; O'Neil, BJ.; Travers, AH. (2010). "Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S787–817. doi:10.1161/CIRCULATIONAHA.110.971028. PMID 20956226. Unknown parameter |month= ignored (help)